Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Plasma cell 1

Conditions

Leukemia 4Myelodysplastic Syndromes 2Multiple Myeloma 2Leukemia, Myeloid, Acute 2Recurrence 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Neoplasms, Plasma Cell 1Lymphoma 1Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative 1Leukemia, Myeloid 1Hodgkin Disease 1Hematologic Neoplasms 1Congenital Abnormalities 1Blast Crisis 1

Interventions

Dexamethasone 29Cyclophosphamide 21Rituximab 17Cytarabine 16Bortezomib 13Gemcitabine 12fludarabine 11Methotrexate 11Lenalidomide 10Filgrastim 10Vincristine 9Etoposide 9pomalidomide 8pembrolizumab 8Paclitaxel 8Azacitidine 8venetoclax 7carfilzomib 7Doxorubicin 7Docetaxel 7Cyclosporine 7Calcium Dobesilate 7Antilymphocyte Serum 7fludarabine phosphate 6Topotecan 6Temozolomide 6Radiotherapy 6Peripheral Blood Stem Cell Transplantation 6Mitoxantrone 6daratumumab 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Recurrence × Methylprednisolone Acetate × Clear all
NCT02294357 2023-11-01

Weekly 70 mg/m2 Carfilzomib for Multiple Myeloma Patients Refractory to 27 mg/m2 Carfilzomib

Oncotherapeutics

Phase 2 Terminated
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡